KR20220088078A - Composition for cultivating cordyceps sinensis containing barley and cheonma as active ingredients and method for culturing cordyceps sinensis using the same - Google Patents

Abstract

The present invention relates to providing anti-inflammatory, anti-obesity, and bone disease prevention and improvement effects with a composition for culturing Cordyceps Cordyceps and an extract of Cordyceps Cordyceps cultured by a method of culturing Cordyceps Cordyceps as an active ingredient, comprising barley and Chunma as active ingredients.

Description

Composition for cultivating cordyceps sinensis containing barley and cheonma as active ingredients and method for culturing cordyceps sinensis using the same}

The present invention relates to a composition for culturing Cordyceps Cordyceps containing barley and chrysanthemum as active ingredients and a method for culturing Cordyceps cordyceps using the same. It is to confirm that the minute is increased, and to provide a pharmaceutical composition, a food composition and a feed composition because it has excellent bone health and anti-obesity and anti-inflammatory effects when using the Cordyceps cordyceps cultured composition.

Vegetable worms mostly parasitize insects and are characterized by producing fruiting bodies on the corpses of host insects. Depending on the type of host, there are Cordyceps militaris, which uses butterflies as a host, C. sobolifera, which uses cicadas as a host, and C. sphecocephala, which uses bees as a host, and other beetles and grasshoppers. , there is also Cordyceps Cordyceps, which hosts spiders.

It is known to have effects such as strengthening immune function, anticancer, recovery of respiratory function, suppression of aging, recovery from fatigue, and suppression of obesity and anemia.

The Cordyceps mushroom is commonly reported to have an anti-cancer effect and an immune-enhancing effect, and is widely used in the manufacture of functional foods and health supplements as well as pharmaceuticals. To use Cordyceps Cordyceps as a mixed raw material for pharmaceuticals and functional foods, mushrooms, which are fruiting bodies, must be collected and used. .

In addition, a method of cultivating fruiting bodies using sawdust or the like is sometimes used, but this method also takes several months of cultivation period. In order to supply raw materials to the extent that they can be used industrially, the demand for mass production cannot be met due to the difficulty that a large amount of production facilities and expenses are required.

As such, although Cordyceps Cordyceps is effective as an anticancer agent and an immune enhancer, its supply is limited, and mass production and rapid production are not easy, so it is not widely used.

Therefore, research on a mass culture method capable of producing a mycelium exhibiting an effect equivalent to that of a fruiting body of a mushroom fungus has been actively conducted recently.

Under this background, the present inventors have studied the introduction of a method of culturing the Cordyceps mycelium in a medium containing barley and horseradish in order to add pharmacological effects such as anti-inflammatory, anti-obesity, and bone health promoting effects, barley and By confirming that Cordyceps Cordyceps can be effectively cultured even when other components are not added in the composition containing only Chunma as an active ingredient, the present invention has been completed.

One object of the present invention is to provide a composition for culturing Cordyceps Cordyceps, which includes barley and Chunma as active ingredients.

Another object of the present invention is to provide a method for culturing Cordyceps cordyceps, comprising a first step of culturing a Cordyceps strain in a medium containing barley and chrysanthemum as active ingredients to produce a Cordyceps fruiting body and a second step of growing and cultivating the Cordyceps fruiting body. will do

Another object of the present invention is a functional component of Cordyceps Cordyceps, comprising a first step of culturing a Cordyceps strain in a medium containing barley and Chunma as active ingredients to produce a Cordyceps fruiting body and a second step of growing and cultivating the Cordyceps Cordyceps fruiting body. It provides a way to promote it.

Another object of the present invention is to provide a Cordyceps Cordyceps cultured by the culturing method of the present invention.

Another object of the present invention is to provide a health functional food composition for improving immunity comprising the extract of Cordyceps Cordyceps as an active ingredient.

Another object of the present invention is to provide an anti-inflammatory health functional food composition comprising the extract of Cordyceps Cordyceps as an active ingredient.

Another object of the present invention is to provide a health functional food composition for preventing or improving cancer comprising the extract of Cordyceps Cordyceps as an active ingredient.

Another object of the present invention is to provide a health functional food composition for anti-obesity comprising the extract of Cordyceps Cordyceps as an active ingredient.

Another object of the present invention is to provide a health functional food composition for preventing or improving bone disease comprising the extract of Cordyceps Cordyceps as an active ingredient.

Another object of the present invention is to provide an anti-inflammatory pharmaceutical composition comprising the extract of Cordyceps Cordyceps as an active ingredient.

Another object of the present invention is to provide an anti-inflammatory feed composition comprising the extract of Cordyceps Cordyceps as an active ingredient.

Another object of the present invention is to provide a pharmaceutical composition for preventing or improving cancer comprising the extract of Cordyceps Cordyceps as an active ingredient.

Another object of the present invention is to provide a feed composition for preventing or improving cancer comprising the extract of Cordyceps Cordyceps as an active ingredient.

Another object of the present invention is to provide a pharmaceutical composition for anti-obesity comprising the extract of Cordyceps Cordyceps as an active ingredient.

Another object of the present invention is to provide a feed composition for anti-obesity comprising the extract of Cordyceps Cordyceps as an active ingredient.

Another object of the present invention is to provide a pharmaceutical composition for preventing or improving bone disease comprising the extract of Cordyceps Cordyceps as an active ingredient.

Another object of the present invention is to provide a feed composition for preventing or improving bone disease, comprising the extract of Cordyceps Cordyceps as an active ingredient.

Another object of the present invention is to provide an extract of Cordyceps Cordyceps extract, wherein the extract of Cordyceps sinensis is extracted with one or more extraction solvents selected from the group consisting of methanol (MeOH), water and pretanol (prethano).

This will be described in detail as follows. Meanwhile, each description and embodiment disclosed in the present invention may be applied to each other description and embodiment. That is, all combinations of the various elements disclosed herein fall within the scope of the present invention. In addition, it cannot be considered that the scope of the present invention is limited by the specific descriptions described below.

Hereinafter, the present invention will be described in more detail.

A first aspect of the present invention for achieving the above object provides a composition for culturing Cordyceps Cordyceps, which includes barley and Chunma as active ingredients.

As used herein, the term "barley" refers to a crop belonging to the Grape family containing a large amount of dietary fiber, which helps to nourish and control blood sugar. Specifically, it may include a variety of Saesal, Saechal, Nurichal, or Beta-one. More specifically, it may be a beta-one variety.

The barley may be included in an amount of 60% to 80% by weight compared to the composition for culturing Cordyceps Cordyceps, but is not limited thereto.

As used herein, the term "Cheonma" is a multi-year-old parasitic plant and means living attached to the mycelium of a mushroom that grows on a rotten stump of an oak tree. Specifically, the scientific name is Gastrodia elata BLUME0, and it has sedative and antispasmodic effects, and the applied diseases include headache or dizziness, as well as symptoms of stiffening and numbness of the muscles of the limbs, hemiplegia, speech disorders, high blood pressure, and epilepsy in children. , is known to have medicinal effects on diseases such as epidemic meningitis.

The cheonma may be included in an amount of 20% to 40% by weight compared to the composition for culturing Cordyceps cordyceps, but is not limited thereto.

As used herein, the term "Cordyceps Cordyceps" is an insect parasitic medicinal mushroom, named after being in an insect body in winter and appearing like grass in summer, and refers to a mushroom that is effective in anti-cancer, immunity, and anti-aging. Specifically, the Cordyceps strain refers to a microorganism having a genetically homogeneous nucleus that is purely isolated and cultured, and may be a Dodong, Dowon, or Gangwon spawn. More specifically, it may be a Gangwon spawn.

As used herein, the term "cultivation" refers to an operation or medium, means, temperature, pH, humidity, oxygen presence or the like for artificially growing and proliferating a part of a microbial plant animal egg, animal or plant tissue.

Specifically, the culture composition of the present invention may be a medium in which Cordyceps Cordyceps is cultured, specifically, it may be to enhance the contents of cordycepin and beta-glucan.

Cordyceps that is cultured with the culture composition has an improved content of cordycepin and beta-glucan, and this cordyceps may provide an effect of inhibiting NO production, inhibiting cytokine activity, inhibiting adipocyte differentiation, and inhibiting osteoclast differentiation.

As used herein, the term "codycepin" is a natural drug that has a structure similar to that of adenosine and can cause early termination of protein synthesis. It means that there are various pharmacological actions such as oxygen removal. Specifically, in general, it can be extracted from Cordyceps Cordyceps, and the content of cordycepin contained in wild Cordyceps is extremely small and the content is not stable, so extraction is difficult.

As used herein, the term "beta glucan (β-glucan)" refers to a type of polysaccharide that has an immune enhancing action and is present in the cell wall of yeast, mushrooms, grains, and the like. Specifically, it may be to inhibit the proliferation and recurrence of cancer cells by activating the immune function of normal human cells, reduce blood sugar and blood cholesterol, and improve lipid metabolism to suppress body fat formation and accumulation.

As used herein, the term "inhibition of NO production" refers to inhibiting the promotion of inflammatory responses such as vascular permeability and edema by the generation of NO appearing in an inflammatory state. Specifically, NO not only promotes inflammatory reactions such as vascular permeability and edema, but also promotes biosynthesis of inflammatory mediators, expands blood vessels, inhibits cancer tissue growth, inhibits proliferation of viruses or bacteria, or directly kills, etc. It plays an important role in the body's immune-inflammatory response. Therefore, it is essential to examine the inhibition of NO production for substances having anti-inflammatory activity, and the anti-inflammatory effect can be confirmed by the inhibition rate of NO production.

As used herein, the term “cytokine” refers to proteins secreted by immune cells. After cytokines are secreted from cells, they can affect other cells or the cells themselves. That is, it induces the proliferation of macrophages or promotes the differentiation of secretory cells themselves. Cytokines act through receptors and are particularly important in the immune system. Cytokines are also important in maintaining health and in disease, especially in the body's response to infections, immune responses, inflammation, trauma, sepsis, cancer and reproduction.

When pathogens and viruses enter the host, it recognizes the pathogen and sends a signal to activate the transcription factor NF-kB, which induces inflammatory gene material (cytokine) to cause various diseases. Cordyceps of the present invention was confirmed to exhibit an anti-inflammatory effect by inhibiting NO production and cytokine activity.

In addition, additives may be additionally added to the culture composition, and the additives may include, for example, other growth-promoting compounds, growth factors, or amino acids.

In addition, the second aspect of the present invention is a method of culturing Cordyceps Cordyceps, comprising a first step of culturing a Cordyceps strain in a medium containing barley and Chunma as active ingredients to produce a Cordyceps fruiting body, and a second step of growing and cultivating the Cordyceps Cordyceps fruiting body. to provide.

As used herein, the term “fruiting body” refers to an organ that produces spores of a fungus. Specifically, it is a complex structure made by a fungus for spore formation, and a large fruiting body is called a mushroom.

As used herein, the term "cultivation" refers to raising a crop by cultivating crops on arable land with a certain purpose to develop and grow large.

In addition, the third aspect of the present invention is a functional component of Cordyceps Cordyceps comprising a first step of culturing a Cordyceps strain in a medium containing barley and chrysanthemum as active ingredients to produce a Cordyceps fruiting body and a second step of growing and cultivating the Cordyceps fruiting body. provide a way to promote it.

The functional components of the Cordyceps Cordyceps are known, such as beta-glucan, cordycepine, cordycepic acid (Codycepic acid, Mannitol), codycepic polysaccharide, superoxide dismutase (SOD), amino acids, and vitamin precursors, specifically, Cordycepin and beta-glucan content can be enhanced by the method for enhancing the functional ingredients of the present invention, but is not limited thereto.

In addition, a fourth aspect of the present invention provides a Cordyceps Cordyceps cultured by the culturing method of the present invention.

In addition, a fifth aspect of the present invention provides a health functional food composition for improving immunity comprising the extract of Cordyceps Cordyceps as an active ingredient.

In addition, a sixth aspect of the present invention provides an anti-inflammatory health functional food composition comprising the extract of Cordyceps Cordyceps as an active ingredient.

In addition, a seventh aspect of the present invention provides a health functional food composition for preventing or improving cancer comprising the extract of Cordyceps Cordyceps as an active ingredient.

In addition, an eighth aspect of the present invention provides a health functional food composition for anti-obesity comprising the extract of Cordyceps Cordyceps as an active ingredient.

In addition, a ninth aspect of the present invention provides a health functional food composition for preventing or improving bone disease comprising the extract of Cordyceps Cordyceps as an active ingredient.

In addition, a tenth aspect of the present invention provides an anti-inflammatory pharmaceutical composition comprising the extract of Cordyceps Cordyceps as an active ingredient.

In addition, an eleventh aspect of the present invention provides an anti-inflammatory feed composition comprising the extract of Cordyceps Cordyceps as an active ingredient.

In addition, a twelfth aspect of the present invention provides a pharmaceutical composition for preventing or improving cancer comprising the extract of Cordyceps Cordyceps as an active ingredient.

In addition, a thirteenth aspect of the present invention provides a feed composition for preventing or improving cancer comprising the extract of Cordyceps Cordyceps as an active ingredient.

In addition, a fourteenth aspect of the present invention provides a pharmaceutical composition for anti-obesity comprising the extract of Cordyceps Cordyceps as an active ingredient.

In addition, a fifteenth aspect of the present invention provides an anti-obesity feed composition comprising the extract of Cordyceps Cordyceps as an active ingredient.

In addition, a sixteenth aspect of the present invention provides a pharmaceutical composition for preventing or improving bone disease comprising the extract of Cordyceps Cordyceps as an active ingredient.

In addition, a seventeenth aspect of the present invention provides a feed composition for preventing or improving bone diseases comprising the extract of Cordyceps Cordyceps as an active ingredient.

As used herein, the term “anti-inflammatory” refers to inhibiting or preventing inflammation, and is not particularly limited, but may be caused by cell damage or external infectious agents.

The "inflammation" refers to tissue (cell) damage or infection with external infectious agents (bacteria, viruses, fungi, various types of allergens), enzyme-activated inflammation due to the involvement of various inflammatory mediators and immune cells in local blood vessels and body fluids It exhibits a series of complex physiological reactions such as mediator secretion, body fluid infiltration, cell migration, and tissue destruction, and external symptoms such as erythema, edema, fever, and pain. In normal cases, the inflammatory response removes external infectious agents and regenerates damaged tissues to restore the function of life, but if the antigen is not removed or the internal substance is the cause and the inflammatory response is excessive or continuous, it rather promotes mucosal damage. diseases such as cancer.

As used herein, the term “inflammation-related disease” refers to a disease in which inflammation is the main lesion. Inflammation is a non-specific response mediated by innate immunity, and when caused by a pathogen, it occurs regardless of the type of pathogen or previous infection. In addition to innate immunity, some local adaptive immunity are also involved in inflammation. Inflammation has a protective function to cure infection or promote tissue regeneration, but at the same time, tissue damage or disease can occur as a result of inflammation. There is also a method of intentionally inducing an inflammatory response, such as prolotherapy, to attempt tissue regeneration. Specifically, it may include Behcet's disease, Crohn's disease, rheumatoid arthritis, hair follicles, seborrheic dermatitis, psoriasis, lupus, chronic obstructive pulmonary disease, irritable bowel disease, digestive steatorrhea, vasculitis, and the like.

As used herein, the term “anti-cancer” refers to the effect of preventing cancer cell proliferation and resisting cancer. Specifically, the cancer is thyroid cancer, stomach cancer, colon cancer, lung cancer, breast cancer, liver cancer, prostate cancer, pancreatic cancer, gallbladder cancer, biliary tract cancer, non-Hodgkin's lymphoma, blood cancer, skin cancer, bone cancer, heart cancer, adrenal cortical cancer, anal cancer, appendix cancer, gallbladder cancer, bladder cancer, testicular cancer, ovarian cancer, esophageal cancer, brain cancer, nasopharyngeal cancer, and the like.

As used herein, the term “reducing body fat” refers to an effect of reducing body fat to reduce body fat, and inhibiting an increase in body fat to suppress an increase in body fat, even though there is no change in body weight.

As used herein, the term “obesity” refers to a state in which adipose tissue is excessive as an energy imbalance in the body that occurs when the body consumes more energy than the body needs or consumes less energy than the intake energy. Specifically, obesity is mainly caused by an increase in the amount of pre-adipocytes in the body differentiated into adipocytes due to the accumulation of fat, and may cause obesity-related diseases.

As used herein, the term “obesity-related disease” refers to a disease caused by excessive accumulation of fat cells due to obesity, resulting in various abnormalities. Substances called adipokines secreted from fat cells regulate body metabolism, and obesity causes an imbalance of these substances, resulting in abnormalities in fat and glucose metabolism. Specifically, obesity-related diseases include hypertension, diabetes, hyperlipidemia, fatty liver, cholelithiasis, obstructive sleep apnea, menstrual irregularity, polycystic ovarian disease, infertility, decreased libido, depression, degenerative arthritis, gout, colon cancer, pancreatic cancer, prostate cancer, breast cancer, etc. It may include various cancers.

As used herein, the term "bone disease" is not particularly limited, but specifically, may be osteoporosis, osteomalacia, rickets, Paget's disease, scoliosis, osteomyelitis, benign bone tumor, or Paget's disease.

The "osteoporosis" is a skeletal disease in which bone strength is weakened and fractures easily. Specifically, genetic factors, early menopause, drugs (steroids), comorbid diseases, smoking, alcohol, rheumatoid arthritis, etc. may be the cause, and a problem may have occurred in the process of bone remodeling, most of which are asymptomatic but fracture When this occurs, pain occurs, and various symptoms may appear depending on the site of the fracture.

As used herein, the term "bone remodeling process" consists of osteoblasts and osteoclasts. Osteoblasts are involved in the process of bone formation to create new bones, and osteoclasts are involved in bone resorption that destroys old bones. Specifically, when female hormone deficiency appears due to menopause, it directly or indirectly affects osteoblasts and osteoclasts involved in this bone remodeling process, leading to bone loss. That is, after menopause, bone remodeling becomes active and the degree of bone resorption is greater than the degree of bone formation, which causes bone loss.

As used herein, the term “prevention” refers to any action that inhibits or delays the onset of inflammation by administration of the pharmaceutical composition according to the present invention.

As used herein, the term "improvement" refers to any action that at least reduces a parameter, for example, the severity of a symptom, associated with a condition to be treated by administration of a composition according to the present invention.

As used herein, the term "treatment" refers to any action in which the symptoms of the subject suspected of inflammation and the onset of the disease are improved or beneficially changed by the administration of the pharmaceutical composition.

The composition of the present invention may further include a pharmaceutically acceptable salt.

Another embodiment of the present invention for achieving the above object is for improving immunity or anti-inflammatory, cancer prevention or improvement, including Cordyceps Cordyceps, an extract of Cordyceps Cordyceps, or a pharmaceutically acceptable salt thereof, cultured by the above culture method. It provides a health functional food composition for obesity, and prevention or improvement of bone disease.

Another embodiment of the present invention for achieving the above object is that the Cordyceps Cordyceps according to the present invention, the extract of Cordyceps Cordyceps exhibits excellent anti-inflammatory, anti-cancer, anti-obesity and bone disease improvement and prevention effects, thus preventing or improving inflammation, anti-cancer, anti-inflammatory It may be included in a food composition for the purpose of preventing and improving obesity, bone disease, and since the food composition can be consumed on a daily basis, it has a high effect on prevention or improvement of inflammation, anticancer, anti-obesity, prevention and improvement of bone disease can be expected

In this case, the descriptions of “cord Cordyceps”, “inflammation”, “anti-cancer”, “obesity”, “bone disease”, “improvement” and “prevention” are the same as described above.

As used herein, the term “health functional food” refers to food manufactured and processed using raw materials or ingredients useful for the human body in accordance with Act No. 6727 of the Health Functional Food Act, and 'functionality' refers to the structure of the human body. And it means to obtain a useful effect for health use, such as regulating nutrients for function or physiological action. On the other hand, health food means food that has an active health maintenance or promotion effect compared to general food, and health supplement means food for the purpose of health supplementation. In some cases, the terms health functional food, health food and health supplement food can be mixed.

Cordyceps Cordyceps, extract of Cordyceps Cordyceps, or a pharmaceutically acceptable salt thereof of the present invention may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method.

The food of the present invention can be prepared by a method commonly used in the art, and at the time of manufacture, it can be prepared by adding raw materials and components commonly added in the art. Specifically, the food composition may further include a physiologically acceptable carrier, the type of carrier is not particularly limited and any carrier commonly used in the art may be used. In addition, the food composition contains food additives such as preservatives, disinfectants, antioxidants, colorants, coloring agents, bleaching agents, seasonings, sweeteners, flavoring agents, expanding agents, strengthening agents, emulsifying agents, thickeners, filming agents, gum base agents, foam inhibitors, solvents, and improving agents. may include The additive may be selected according to the type of food and used in an appropriate amount.

In addition, the formulation of the food may be prepared without limitation as long as it is a formulation recognized as a food. The composition for food of the present invention can be prepared in various forms, and unlike general drugs, it has the advantage that there are no side effects that may occur when taking the drug for a long period of time using food as a raw material, and it is excellent in portability, so the present invention The food of can be consumed as an adjuvant to enhance the effect of preventing or improving inflammation, anticancer, anti-obesity, and preventing or improving bone disease.

Cordyceps Cordyceps or a pharmaceutically acceptable salt thereof of the present invention may be included in various weight % in the food composition if it can exhibit the effect of improving immunity or anti-inflammatory, preventing or improving cancer, anti-obesity, and preventing or improving bone disease. Specifically, it may be included in an amount of 0.00001 to 100% by weight or 0.01 to 80% by weight relative to the total weight of the food composition, but is not limited thereto. In the case of long-term ingestion for health and hygiene purposes, it may contain an amount below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.

Another embodiment of the present invention for achieving the above object is for improving immunity or anti-inflammatory, cancer prevention or improvement, including Cordyceps Cordyceps, an extract of Cordyceps Cordyceps, or a pharmaceutically acceptable salt thereof, cultured by the above culture method. It provides a feed composition for obesity and bone disease prevention or improvement.

At this time, the description of "Cordyceps Cordyceps", "Foodly acceptable salt", "Anti-inflammatory", "Inflammation", "Anti-cancer", "Obesity", "Bone disease", "Prevention" and "Improvement" is above as described in

Cordyceps according to the present invention, the extract of Cordyceps Cordyceps, or a pharmaceutically acceptable salt thereof exhibits excellent anti-inflammatory, anti-cancer, anti-obesity, bone disease prevention and improvement effects, and thus improves immunity or anti-inflammatory, cancer prevention or improvement, anti-obesity , and may be included in a feed composition for the purpose of preventing or improving bone diseases, and since the feed composition can be consumed by animals on a daily basis, a high effect can be expected for the prevention or improvement of inflammation and anticancer.

As used herein, the term "feed" means any natural or artificial diet, meal, etc., or a component of said meal, intended for or suitable for being eaten, consumed, and digested by an animal. The type of feed is not particularly limited, and feed commonly used in the art may be used. Non-limiting examples of the feed include plant feeds such as grains, root fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, gourds or grain by-products; and animal feeds such as proteins, inorganic materials, oils and fats, minerals, oils and fats, single cell proteins, zooplankton or food. These may be used alone or in mixture of two or more.

Another embodiment of the present invention for achieving the above object is for improving immunity or anti-inflammatory, cancer prevention or improvement, including Cordyceps Cordyceps, an extract of Cordyceps Cordyceps, or a pharmaceutically acceptable salt thereof, cultured by the above culture method. It provides a pharmaceutical composition for obesity, and prevention or improvement of bone disease.

The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent, wherein the carrier may include a non-naturallyoccuring carrier.

As used herein, the term "pharmaceutically acceptable salt" refers to a salt in a form that can be used pharmaceutically among salts, which are substances in which a cation and an anion are combined by electrostatic attraction, and is usually a metal salt, an organic base and salts, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids, and the like. For example, the metal salt may be an alkali metal salt (sodium salt, potassium salt, etc.), alkaline earth metal salt (calcium salt, magnesium salt, barium salt, etc.), an aluminum salt or the like; Salts with organic bases include triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N-dibenzylethylenediamine salts with, etc.; salts with inorganic acids may be salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like; Salts with organic acids may be salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like; Salts with basic amino acids may be salts with arginine, lysine, ornithine and the like; The salt with an acidic amino acid may be a salt with aspartic acid, glutamic acid, or the like.

Specifically, carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium Silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, polycaprolactone, polylactic acid Lactic Acid), poly-L-lactic acid, and mineral oil. The pharmaceutical composition may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injection solutions, respectively, according to conventional methods. The form may include various amorphous carriers, microspheres, nanofibers, and the like. In the case of formulation, it can be prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, surfactant, etc. commonly used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the extract and its fractions, for example, starch, calcium carbonate, It may be prepared by mixing sucrose or lactose, gelatin, or the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid formulations for oral administration include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. The content of Cordyceps Cordyceps or a pharmaceutically acceptable salt thereof contained in the pharmaceutical composition of the present invention is not particularly limited.

In addition, the eighteenth aspect of the present invention provides an extract of Cordyceps Cordyceps, wherein the extract of Cordyceps Cordyceps is extracted with one or more extraction solvents selected from the group consisting of methanol (MeOH), water and pretanol (prethano).

As used herein, the term "extract" means a substance separated by a solvent from a liquid or solid mixture.

The extract may be prepared at a concentration of 1 μg/ml to 10 μg/ml, but is not limited thereto.

In a specific example, Cordyceps cultured with the composition for culturing Cordyceps Cordyceps of the present invention has increased contents of cordycepin and beta-glucan, and when such Cordyceps Cordyceps is included, NO production inhibition, cytokine production inhibition, adipocyte differentiation inhibition, and osteoclast The cell differentiation inhibitory effect was confirmed.

More specifically, when the Cordyceps Cordyceps of the present invention uses barley of the beta-one variety and the extraction solvent is extracted with methanol, the content of cordycepin and beta-glucan is higher than when grown in other varieties and extracts extracted with other extraction solvents. improved (Example 3), thereby effectively inhibiting adipocyte differentiation (Example 7) and also effectively inhibiting osteoclast differentiation (Example 8).

Therefore, it was confirmed that the Cordyceps Cordyceps Cordyceps or the extract of Cordyceps Cordyceps of the present invention has anti-inflammatory, anti-cancer, anti-obesity, bone disease prevention and improvement uses, and furthermore, inflammation, obesity, and bone-related diseases and cancer. It suggests that it can be used for preventing, improving, or treating.

Cordyceps cultured by the Cordyceps culture method of the present invention does not show cytotoxicity, and at the same time suppresses NO production, suppresses cytokine production, suppresses adipocyte differentiation, and suppresses osteoclast differentiation. can be used

1 is a graph showing the cordycepin content of the extract of the Cordyceps Cordyceps extract of the present invention by changing the extraction solvent.
Figure 2 is a graph showing the cytotoxicity of the Cordyceps extract of the present invention.
3 is a graph showing the NO production inhibitory activity of the Cordyceps Cordyceps extract of the present invention.
4 is a graph showing the inhibitory effect on the cytokine (TNF-α) content of LPS-stimulated macrophages of the Cordyceps Cordyceps extract of the present invention.
5 is a graph showing the inhibitory effect on the cytokine (IL-6) content of LPS-stimulated macrophages of the Cordyceps Cordyceps extract of the present invention.
6 is a photograph showing the effect of inhibiting the differentiation of adipocytes by extraction solvent of the Cordyceps Cordyceps extract of the present invention.
7 is a photograph showing the effect of inhibiting the differentiation of adipocytes by concentration of the Cordyceps Cordyceps extract of the present invention.
8 is a photograph showing the osteoclast differentiation inhibitory effect at a concentration of 1 μg/ml of the Cordyceps Cordyceps extract of the present invention.
Figure 9 is a photograph showing the osteoclast differentiation inhibitory effect of the extract of the Cordyceps Cordyceps extract of the present invention by changing the extraction solvent.

Hereinafter, the present invention will be described in more detail through examples. These Examples are for explaining the present invention in more detail, and the scope of the present invention is not limited by these Examples.

Example 1: Cordyceps culturing method

Potato river medium (PDA, soy flour, sugar, MgSO ₄ , KH ₂ PO ₄ ) was used to propagate the progenitors of Sanghwang mushroom and Cordyceps. Potato stream medium (PDA, soy flour, sugar, MgSO ₄ , KH ₂ PO ₄ ), 40 g of barley, and an antifoaming agent were placed in a sterile glass bottle and shaken at 21° C. to proliferate the progenitor. 30g of Chunma and 40g of barley were first steamed and sterilized to make a fruiting medium for Cordyceps Cordyceps. Cordyceps fungus was inoculated into the fruiting medium of Cordyceps Cordyceps, and darkly cultured with shaking. The Cordyceps fruiting medium was grown and cultivated for 44 days until the average length of the fruiting body was 4 to 6 cm by maintaining the conditions of a temperature of 19° C. to 21° C., a humidity of 60% to 80%, and an illuminance of 1200Lux to 1300Lux in a growth room.

Example 2: Method for preparing an extract of Cordyceps Cordyceps

The Cordyceps Cordyceps of Example 1 was dried at 45° C. and then pulverized. 100 g of Cordyceps Cordyceps powder was extracted three times with 1L 50% MeOH, water, and pretanol (prethanol, alcohol, ethanol) in different extraction solvents, filtered, and then vacuum-evaporated with a rotary vacuum device (Eyela Co., Ltd., Shanghai, China). was used to concentrate.

Example 3: Cordycepin and beta-glucan content analysis of Cordyceps extract

As shown in Table 1 below, the Cordyceps Cordyceps extract of Example 2 was prepared with different varieties of barley, and cordycepin, total glucan content, alpha-glucan and beta-glucan content were analyzed by liquid chromatography (LC).

barley variety B 2. Heavenly Horse Cordycepin (mg/g) Total glucan (%) α-Glucan (%) β-Glucan (%) fresh rice B2-1.whole 1.35 70.20 10.23 59.97 new sticky rice B2-2.whole 2.44 53.62 9.91 43.70 Nurical B2-6.whole 1.83 42.17 11.61 30.56 beta one B2-10.whole 2.40 29.64 11.63 18.01

As shown in Table 1 and Figure 1, the variety of barley is Saesal (B2-1), Saesal (B2-2), Nurichal (B2-6), and Beta-one (B2-10) of Saesal or Beta-won. had the highest content of cordycepin (Table 1), and among cordyceps extracts extracted with water, pretanol, and 50% MeOH, the cordycepin extract extracted with 50% MeOH had the highest content of cordycepin (Fig. 1). Therefore, it was confirmed that the Cordyceps Cordyceps extract of the present invention was grown with Sachaal rice and Beta-one varieties, and the Cordyceps Cordyceps extract extracted with 50% MeOH showed the best results in anti-inflammatory effect.

Example 4: Cytotoxicity assay

As in Example 3, extracts of Cordyceps Cordyceps grown in different varieties of barley were prepared for each concentration, and their cell viability was measured and cytotoxicity was analyzed.

As shown in Figure 2, the Cordyceps Cordyceps extract of the present invention (B2-1, B2-2, B2-6, B2-10) at each concentration (1, 3, 10 μg / ml) cell viability was measured as a result of the cytotoxicity You can see what is not shown.

Example 5: NO production inhibition assay

RAW 264.7 macrophages were divided into 96 well plates at 5 × 104 cells/well, cultured for 12 to 20 hours, and treated with 1 μg/mL LPS and alcohol extract at different concentrations (1, 3, 10 μg/mL) to 24 time incubation. After incubation, 100 μL of the supernatant was obtained, and the same amount of grease reagent (1% sulfanilamide: 0.1% naphthylenthylenediamine = 1:1) was added and reacted at room temperature for 10 minutes. The absorbance of the reaction solution was measured at 550 nm using a microplate reader (VERSAmax, Molecular Devices, LLC.). The concentration of nitrite was calculated by substituting it into a standard curve obtained using sodium nitrite (FUJIFILM Wako Pure Chemical Co., Osaka, Japan) as a standard material.

As shown in FIG. 3 , the amount of NO production was increased 1845 times in the LPS-only group compared to the LPS-untreated group, resulting in an excessive inflammatory response. However, when the Cordyceps Cordyceps extract of the present invention (B2-1, B2-2, B2-6, B2-10) was treated at 1, 3, and 10 μg/mL, NO production was inhibited in a concentration-dependent manner compared to the LPS alone treatment group. When treated with 10 μg/mL, it was confirmed that the anti-inflammatory effect of the extract (B2-10) of Cordyceps Cordyceps (B2-10) grown with the barley cultivar beta-source was confirmed by suppressing the production of 15.76%, 23.88%, 26.29%, and 36.09% of NO, respectively. .

Example 6: Cytokine activity analysis of macrophages stimulated with LPS

RAW 264.7 macrophages were seeded in 96 well plates at 5×104 cells/well and cultured for 12 to 20 hours, then treated with LPS at 1 μg/mL and BTE at 100, 300, or 500 μg/mL and cultured for 24 hours. TNF-α and IL-6 cytokine content in the cell culture was quantified using a mouse Duoset enzyme-linked immunosorbent assay (ELISA, R&D Systems Inc., Minneapolis, MN, USA). . 100 μL of the capture antibody was dispensed on a microplate and coated overnight, washed with phospho buffered saline (PBS; PBST) containing 0.05% Tween 20, and 1% bovine serum After blocking with PBS containing albumin (bovine serum albumin), washed with PBST(), aliquoted samples, and reacted at room temperature for 2 hours. After the reaction, washed with PBST, treated with a detection antibody, reacted at room temperature for 2 hours, washed with PBST, and aliquoted with streptavidin-horseradish peroxidase conjugate and 20 at room temperature. After reacting for a minute, washed with PBST, put a substrate solution, and reacted in the dark at room temperature for 20 minutes, and the reaction was terminated by adding a reaction stop solution. Using a microplate reader (VERSAmax, Molecular Devices, LLC.) Absorbance was measured at 540 nm.

4 to 5, the Cordyceps Cordyceps extract of the present invention (B2-1, B2-2, B2-6, B2-10) at each concentration (1, 3, 10 μg/ml) compared to the LPS alone treatment group At a concentration of 10 μg/mL, cytokine TNF-α content was reduced by 54.96%, 61.63%, 61.78%, and 75.98%, respectively, and cytokine IL-6 content was inhibited by 35.34%, 50.73%, 61.45%, and 92.42%, respectively. It was confirmed that it provided an anti-inflammatory effect in a concentration-dependent manner, and it was confirmed that the extract (B2-10) of Cordyceps Cordyceps grown as a barley variety beta-source had the best anti-inflammatory effect.

Example 7: Adipocyte differentiation inhibition assay

As shown in Table 1, different barley varieties (new rice B2-1, new rice B2-2, nuri-chal B2-6, beta-one B2-10), and the extraction solution as in Example 2, respectively, were used in the present invention. Cordyceps extract was prepared. The extract thus prepared was added to preadipocytes at each concentration (1, 3, 10 μg/ml), the adipocytes were differentiated into adipocytes, and the differentiated cells were stained with oil-red staining to remove fat in adipocytes. After staining, the level of stained fat was compared under a microscope. In this case, undifferentiated pre-adipocytes (Negative) were used as a negative control group, and differentiated pre-adipocytes (Positive) were used as a positive control group.

As shown in FIG. 6 , when the effect of inhibiting adipocyte differentiation by varying the extraction solvent (50% MeOH, water, pretanol) at the extract concentration of 10 μg/ml of the present invention was examined, Cordyceps Cordyceps extract extracted with 50% MeOH extraction solvent It was confirmed that the inhibition of adipocyte differentiation was the most excellent compared to this positive control group. In addition, compared to cordycepin (10 μg/ml), which is known as an anticancer drug, the Cordyceps extract of the present invention has an excellent effect in inhibiting adipocyte differentiation, and compared to ferulic acid, which is known to be effective in strengthening blood sugar and lowering cholesterol. It was confirmed that the Cordyceps Cordyceps extract of the present invention was excellent in the inhibitory effect on adipocyte differentiation.

As shown in FIG. 7 , the extract of the present invention inhibited fat differentiation in a concentration-dependent manner, and it was confirmed that the extract of Cordyceps cordyceps (B2-10) grown as a barley variety beta source had the best effect of inhibiting adipocyte differentiation.

Example 8: osteoclast differentiation inhibition assay

The osteoclast progenitor cells were cultured with macrophage proliferation stimulatory factors to induce differentiation into macrophages and osteoclast differentiation-inducing cytokines were added, and the Cordyceps Cordyceps extract of the present invention prepared as in Example 7 above was added. In order to analyze the inhibition of osteoclast differentiation, molecular markers related to osteoclast differentiation were stained and photographed under an optical microscope for comparison. At this time, undifferentiated osteoclasts (Negative) were used as a negative control group, and differentiated osteoclasts (Positive) were used as a positive control group.

As shown in FIG. 8, the Cordyceps cordyceps extract of the present invention exhibited an osteoclast differentiation inhibitory effect even at a concentration of 1 μg/ml, and as shown in FIG. 9, the Cordyceps Cordyceps extract extracted with 50% MeOH extraction solvent was the most excellent compared to the positive control It was confirmed that it inhibits osteoclast differentiation.

Combining Examples 1 to 8 of the present invention, the Cordyceps Cordyceps extract of the present invention does not show cytotoxicity and at the same time suppresses NO production, suppresses cytokine production, suppresses adipocyte differentiation, and inhibits osteoclast differentiation, thereby showing anti-inflammatory ability It can be confirmed that the effect, anti-obesity effect, and bone disease inhibitory effect are exhibited.

From the above description, those skilled in the art to which the present invention pertains will understand that the present invention may be embodied in other specific forms without changing the technical spirit or essential characteristics thereof. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention, rather than the above detailed description, all changes or modifications derived from the meaning and scope of the claims to be described later and their equivalents.

Claims (28)

A composition for culturing Cordyceps Cordyceps, comprising barley and Chunma as active ingredients.
According to claim 1,
The barley will include Saesal, Saechal, Nurichal, or Beta-one varieties, Cordyceps culturing composition.
The method of claim 1,
The barley will be included in an amount of 60% to 80% by weight compared to the composition for culturing Cordyceps Cordyceps.
According to claim 1,
The Chunma is a composition for culturing Cordyceps Cordyceps, which comprises 20% to 40% by weight compared to the composition for culturing Cordyceps.
The method of claim 1,
The composition for culturing Cordyceps Cordyceps, characterized in that improving the content of cordycepin and beta-glucan, Cordyceps culturing composition.
A first step of culturing the Cordyceps Cordyceps strain in a medium containing barley and Chunma as active ingredients to produce a Cordyceps fruiting body; and
A second step of growing and culturing the Cordyceps fruiting body; Cordyceps culturing method comprising a.
7. The method of claim 6,
The barley will use the new rice, new chalsal, nuri chal, or beta-one variety, Cordyceps culturing method.
7. The method of claim 6,
The barley will contain 60% to 80% by weight compared to the medium, Cordyceps culturing method.
7. The method of claim 6,
The cheonma will include 20% to 40% by weight compared to the medium, Cordyceps culturing method.
7. The method of claim 6,
The method is characterized in that improving the content of cordycepin and beta-glucan, Cordyceps culturing method.
A first step of culturing the Cordyceps Cordyceps strain in a medium containing barley and Chunma as active ingredients to produce a Cordyceps fruiting body; and
The second step of growing and cultivating the fruiting body of Cordyceps Cordyceps.
12. The method of claim 11,
The functional ingredient is a method of enhancing the functional ingredient of Cordyceps Cordyceps, which includes cordycepin or beta-glucan.
Cordyceps Cordyceps cultured by the culturing method according to any one of claims 6 to 10.
A health functional food composition for improving immunity comprising the extract of Cordyceps Cordyceps of claim 13 as an active ingredient.
An anti-inflammatory health functional food composition comprising the extract of Cordyceps Cordyceps of claim 13 as an active ingredient.
A health functional food composition for preventing or improving cancer comprising the extract of Cordyceps Cordyceps of claim 13 as an active ingredient.
A health functional food composition for anti-obesity comprising the extract of Cordyceps Cordyceps of claim 13 as an active ingredient.
A health functional food composition for preventing or improving bone disease comprising the Cordyceps Cordyceps of claim 13 as an active ingredient.
An anti-inflammatory pharmaceutical composition comprising the extract of Cordyceps Cordyceps of claim 13 as an active ingredient.
An anti-inflammatory feed composition comprising the extract of Cordyceps Cordyceps of claim 13 as an active ingredient.
A pharmaceutical composition for preventing or improving cancer comprising the extract of Cordyceps Cordyceps of claim 13 as an active ingredient.
A feed composition for preventing or improving cancer comprising the extract of Cordyceps Cordyceps of claim 13 as an active ingredient.
A pharmaceutical composition for anti-obesity comprising the extract of Cordyceps Cordyceps of claim 13 as an active ingredient.
An anti-obesity feed composition comprising the extract of Cordyceps Cordyceps of claim 13 as an active ingredient.
A pharmaceutical composition for preventing or improving bone disease comprising the extract of Cordyceps Cordyceps of claim 13 as an active ingredient.
A feed composition for preventing or improving bone disease comprising the extract of Cordyceps Cordyceps of claim 13 as an active ingredient.
The extract of any one of claims 14 to 26, wherein the extract of Cordyceps Cordyceps is extracted with one or more extraction solvents selected from the group consisting of methanol (MeOH), water and pretanol (prethano), Cordyceps extract.
28. The method of claim 27,
The extract is prepared at a concentration of 1 μg / ml to 10 μg / ml, Cordyceps Cordyceps extract.

Images